| # | Fund | Position value | Shares | Last move | As of | History |
|---|---|---|---|---|---|---|
| 1 | Venrock Adviser, LLC | $22.2M | 3.2M | ▲New +3.2M sh | Q1 2026 | |
| 2 | Cormorant Asset Management, LP | $20.1M | 2.9M | ▲New +2.9M sh | Q1 2026 | |
| 3 | Squadron Capital Management LLC | $8.8M | 1.3M | ▲New +1.3M sh | Q1 2026 | |
| 4 | BALYASNY ASSET MANAGEMENT L.P. | $6.1M | 878K | ▲New +878K sh | Q1 2026 | |
| 5 | MILLENNIUM MANAGEMENT LLC | $4.7M | 682K | ▲New +682K sh | Q1 2026 | |
| 6 | ADAGE CAPITAL PARTNERS GP, L.L.C. | $3.7M | 538K | ▲New +538K sh | Q1 2026 | |
| 7 | Casdin Capital, LLC | $3.7M | 538K | ▲New +538K sh | Q1 2026 | |
| 8 | Woodline Partners LP | $1.4M | 209K | ▲New +209K sh | Q1 2026 | |
| 9 | Affinity Asset Advisors, LLC | $1.1M | 165K | ▲New +165K sh | Q1 2026 | |
| 10 | UBS Group AG | $846K | 122K | ▲113× Added · +121K sh | Q1 2026 | |
| 11 | AMERIPRISE FINANCIAL INC | $831K | 120K | ▲New +120K sh | Q1 2026 | |
| 12 | ADAR1 Capital Management, LLC | $816K | 118K | ▲New +118K sh | Q1 2026 | |
| 13 | PRICE T ROWE ASSOCIATES INC /MD/ | $691K | 100K | ▲New +100K sh | Q1 2026 | |
| 14 | Tidal Investments LLC | $457K | 66K | ▲New +66K sh | Q1 2026 | |
| 15 | RENAISSANCE TECHNOLOGIES LLC | $457K | 66K | ▲New +66K sh | Q1 2026 | |
| 16 | CANTOR FITZGERALD, L. P. | $279K | 40K | ▲New +40K sh | Q1 2026 | |
| 17 | TD ASSET MANAGEMENT INC | $247K | 36K | ▲New +36K sh | Q1 2026 | |
| 18 | Ikarian Capital, LLC | $235K | 34K | ▲New +34K sh | Q1 2026 | |
| 19 | GEODE CAPITAL MANAGEMENT, LLC | $77K | 11K | ▲New +11K sh | Q1 2026 | |
| 20 | EverSource Wealth Advisors, LLC | $33K | 5K | —Held | Q1 2026 | |
| 21 | ANTIPODES PARTNERS Ltd | $14K | 2K | ▲New +2K sh | Q1 2026 |
Holders and values reflect the 13F filers Arkolith currently tracks, not the entire institutional universe. Counts and totals are a floor, not the full institutional ownership.
| Company | Co-held by | Combined value |
|---|---|---|
| ERASCA INCERAS | 4 funds | $408.4M |
| ORUKA THERAPEUTICS INCORKA | 4 funds | $258.2M |
| DIANTHUS THERAPEUTICS INCDNTH | 4 funds | $215.2M |
| COGENT BIOSCIENCES INCCOGT | 4 funds | $151.7M |
| ORIC PHARMACEUTICALS INCORIC | 4 funds | $71.3M |
| STRUCTURE THERAPEUTICS INCGPCR | 4 funds | $20.0M |
| JANUX THERAPEUTICS INCJANX | 4 funds | $11.0M |
| NVIDIA CORPNVDA | 3 funds | $1.9B |
| AMAZON.COM INCAMZN | 3 funds | $1.5B |
| MICROSOFT CORPMSFT | 3 funds | $1.5B |
| APOGEE THERAPEUTICS INCAPGE | 3 funds | $736.9M |
| META PLATFORMS INC-CLASS AMETA | 3 funds | $654.9M |
Ranked by how many of ANL's institutional holders also hold each name, a cross-fund conviction signal.
| Date | Insider | Role | Action | Shares | Value |
|---|---|---|---|---|---|
| May 13, 2026 | LU YANG | CEO, Director, 10% Owner | Sell (S) | 10 | $132 |
This stock page is the public Follow view. For one current, evidence-backed answer, use capital_change_brief through REST or MCP. It compares tracked 13F changes with qualifying Form 4 activity and cites the SEC evidence.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/stocks/ANL/capital-change-brief"
Use Arkolith's capital_change_brief for ANL. Tell me what changed, whether insider activity corroborates it, and cite the SEC evidence.
13F holdings + Form 4 insider transactions + end-of-day price history + the live filing stream, joined for ANL. Filings are public domain, sourced to SEC EDGAR; price series derived from end-of-day closes.